DENALI THERAPEUTICS INC. - COMMON STOCK

Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS) Program for MPS II (Hunter Syndrome) Supporting Planned Initiation of Phase 2/3 Clinical Trial

10 Feb 2022 08:00:01 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Appointment of Erik Harris to Board of Directors

07 Feb 2022 09:00:01 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Presentations on DNL310 (ETV:IDS) Development Program in MPS II (Hunter Syndrome) at the Upcoming WORLDSymposium™

01 Feb 2022 09:00:01 By Nasdaq GlobeNewswire

Denali Therapeutics Announces FDA Clinical Hold on DNL919 Investigational New Drug (IND) Application

13 Jan 2022 08:00:01 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Progression and Expansion of Broad Therapeutic Portfolio for Neurodegeneration and Expected Key Milestones in 2022

10 Jan 2022 08:00:03 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Strategic Partner Takeda Exercises Option to Co-Develop and Co-Commercialize DNL593 (PTV:PGRN)

17 Nov 2021 08:30:00 By Nasdaq GlobeNewswire

Denali Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

04 Nov 2021 16:01:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Positive Clinical Results and Regulatory Progress for Development Programs in Amyotrophic Lateral Sclerosis (ALS)

06 Oct 2021 16:01:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Upcoming Presentations on EIF2B Activator DNL343 and RIPK1 Inhibitor SAR443820/DNL788 at the 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting

29 Sep 2021 09:00:01 By Nasdaq GlobeNewswire

Denali Therapeutics Appoints Katie Peng as Chief Commercial Officer

27 Sep 2021 09:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS

09 Sep 2021 09:00:01 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Publication in Cell on New Approach to Treat FTD-GRN

26 Aug 2021 11:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II)

25 Jul 2021 11:05:00 By Nasdaq GlobeNewswire

Denali Therapeutics to Present Interim Data from Phase 1/2 Study of ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at MPS 2021

15 Jul 2021 09:00:01 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Initiation of Phase 2 Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in Cutaneous Lupus Erythematosus (CLE) Patients

28 Jun 2021 08:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

03 May 2021 08:30:00 By Nasdaq GlobeNewswire

Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson’s Disease

01 May 2021 09:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment of Patients with Hunter Syndrome (MPS II)

11 Mar 2021 08:30:00 By Nasdaq GlobeNewswire

Denali Therapeutics Reports Full Year 2020 Financial Results and Business Highlights

25 Feb 2021 16:01:01 By Nasdaq GlobeNewswire

Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome (MPS II)

12 Feb 2021 07:30:00 By Nasdaq GlobeNewswire